Mimic antibodies: leveraging ligand mimicry for epitope-targeted antibody discovery.
Mimic antibodies show promise for targeted antibody discovery, but further validation is needed to assess their therapeutic potential.
Where it sits
this study against the rest of the evuzamitide corpusSummary and findings
The study explores mimic antibodies that replicate the binding mode of a target's ligand, using a ligand-guided strategy to identify antibodies with specific epitope targeting. Analysis of the Protein Data Bank revealed widespread mimicry through various structural mechanisms. Screening a 20,000-sequence repertoire for IL-18RA interaction yielded 31 candidates, with 11 binding the IL-18RA D3 domain and eight showing sub-nanomolar affinities.
Abstract
Antibodies are renowned for their ability to bind diverse targets with high affinity and specificity, yet identifying binders with predefined epitope specificity remains a major challenge. In this study, we investigate the concept of mimic antibodies-antibodies that recapitulate the binding mode of a target's cognate ligand. Through a systematic analysis of the Protein Data Bank (PDB), we show that such mimicry is widespread and arises through diverse structural mechanisms, such as single-loop, multi-loop and scattered interaction mimicry. These findings indicate that protein interfaces impose strong constraints on binding, leading to convergent interaction solutions that can be independently discovered by antibodies. Building on these findings, we developed a ligand-guided strategy to mine immune repertoire data by selecting antibodies whose predicted binding interfaces mimic the interaction motif of a cognate ligand. Applied to the interaction between interleukin-18 (IL-18) and its receptor alpha (IL-18RA), mimicry-guided screening of a 20,000-sequence repertoire yielded 31 candidates, 11 of which (35% hit rate) bound the IL-18RA D3 domain, with eight reaching sub-nanomolar affinities that surpass the cognate ligand. Our findings establish mimic antibodies as a promising strategy for rational antibody selection, engineering, and design, with broad implications for therapeutic antibody development and drug discovery.
Background
The study addresses the challenge of identifying antibodies with predefined epitope specificity, a significant hurdle in antibody discovery. Antibodies are known for their high affinity and specificity, yet targeting specific epitopes remains difficult. This research is important as it proposes a novel strategy leveraging ligand mimicry to guide antibody selection, which could enhance therapeutic antibody development.
Methods
The study conducted a systematic analysis of the Protein Data Bank to investigate mimic antibodies. It employed a ligand-guided strategy to screen a 20,000-sequence immune repertoire for antibodies mimicking the interaction motif of the IL-18 and IL-18RA interaction. The primary outcome was the identification of antibodies binding the IL-18RA D3 domain with high affinity.
Results
The analysis revealed widespread mimicry in protein interfaces, suggesting strong constraints on binding. From the 20,000-sequence repertoire, 31 candidates were identified, with 11 binding the IL-18RA D3 domain. Eight of these candidates exhibited sub-nanomolar affinities, surpassing the cognate ligand's affinity.
Interpretation
The findings suggest that mimic antibodies can be a viable strategy for rational antibody selection and design. While the study demonstrates significant binding affinities, the clinical significance remains uncertain without further validation. The reliance on in silico methods and a limited sequence repertoire are notable confounds that may affect the generalizability of the results.
Key findings
- Mimicry is widespread in the Protein Data Bank, arising through diverse structural mechanisms.
- 31 candidates were identified from a 20,000-sequence repertoire.
- 11 candidates bound the IL-18RA D3 domain.
- 8 candidates achieved sub-nanomolar affinities.
Limitations
- In silico analysis only
- Limited sequence repertoire
- No in vivo validation
- Potential overestimation of clinical relevance